삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 김기현 교수

진료분야
다발성골수종, 아밀로이드증, 골수이식, CAR-T세포치료
진료일정 06 月
날짜
일
01
월
02
화
03
수
04
목
05
금
06
토
07
일
08
월
09
화
10
수
11
목
12
금
13
토
14
일
15
월
16
화
17
수
18
목
19
금
20
토
21
일
22
월
23
화
24
수
25
목
26
금
27
토
28
일
29
월
30
오전
오후
진료일정 07 月
날짜
화
01
수
02
목
03
금
04
토
05
일
06
월
07
화
08
수
09
목
10
금
11
토
12
일
13
월
14
화
15
수
16
목
17
금
18
토
19
일
20
월
21
화
22
수
23
목
24
금
25
토
26
일
27
월
28
화
29
수
30
목
31
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2008.08 서울대학교 대학원 의학과 (박사)
2000.02 중앙대학교 대학원 의학과 (석사)
1991.02 서울대학교 의과대학 졸업 (의학사)
1987.02 서울대학교 자연과학대학 의예과 수료

경력

경력
2014.09 ~현재 성균관대학교 의과대학 내과학 교수
2008.09 ~ 2014.08 성균관대학교 의과대학 내과학 부교수
2002.03 ~ 2008.08 성균관대학교 의과대학 내과학 조교수
2001.03 ~ 2002.02 삼성서울병원 혈액종양내과 전문의
2000.03 ~ 2001.02 분당제생병원 내과 전문의
1999.03 ~ 2000.02 삼성서울병원 혈액종양내과 전임의
1999.03 내과 전문의 자격 취득
1995.03 ~ 1999.02 삼성서울병원 내과 레지던트 과정 수료
1991.03 ~ 1992.02 서울대학교병원 인턴과정 수료
논문
  • BMC CANCER 2025 10.1186/s12885-025-13518-0 Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma Kang, KW; Kim, DS; Lee, SR; Heo, MH; Eom, HS; Jung, J; Lee, JH; Kim, SH; Koh, Y; Min, CK; Lee, SS; Lim, SN; Yhim, HY; Lee, MW; Lee, JJ; Jung, SH; Bang, SM; Kim, K
    View PubMed
  • NEW ENGL J MED 2025 10.1056/NEJMoa2406536 Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma Cohen, YC; Magen, H; Gatt, M; Sebag, M; Kim, K; Min, CK; Ocio, EM; Yoon, SS; Chu, MP; Rodriguez-Otero, P; Avivi, I; Carde, NAQ; Kumar, A; Krevvata, M; Peterson, MR; Di Scala, L; Scott, E; Hilder, B; Vanak, J; Banerjee, A; Oriol, A; Morillo, D; Mateos, MV
    View PubMed
  • HAEMATOLOGICA 2024 10.3324/haematol.2024.285534 Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study Lee, JH; Choi, J; Min, CK; Park, SS; Jo, JC; Lee, YJ; Kim, JS; Eom, HS; Jung, J; Moon, JH; Cho, HJ; Lee, MW; Yoon, SS; Byun, JM; Lee, JH; Lee, JJ; Jung, SH; Shin, HJ; Kim, D; Yi, JH; Lee, SS; Do, YR; Yoon, DH; Cho, H; Lee, WS; Lee, HS; Uhm, J; Kim, HJ; Jang, HR; Kim, SH; Kim, K
    View PubMed
  • SCI REP-UK 2024 10.1038/s41598-024-74625-9 Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study Jung, J; Jung, SH; Lee, JJ; Do, YR; Kang, KW; Lee, JL; Yoon, SS; Min, CK; Kang, HJ; Lee, JH; Park, JH; Kim, K; Eom, HS
    View PubMed
  • LANCET HAEMATOL 2024 10.1016/S2352-3026(24)00148-0 Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial Yong, K; Martin, T; Dimopoulos, MA; Mikhael, J; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Casca, F; Macé, S; Risse, ML; Moreau, P
    View PubMed
  • ANN HEMATOL 2024 10.1007/s00277-024-05958-8 Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study Fu, WJ; Bang, SM; Huang, HH; Kim, K; Li, W; An, G; Lee, JJ; Cai, Z; Jin, J; Wang, YF; Chim, CS; Carson, R; Liu, R; Zhao, M; Chen, X; Cui, CC; Hou, J; Wang, JX
    View PubMed
  • NEW ENGL J MED 2024 10.1056/NEJMoa2403407 Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma Dimopoulos, MA; Beksac, M; Pour, L; Delimpasi, S; Vorobyev, V; Quach, H; Spicka, I; Radocha, J; Robak, P; Kim, K; Cavo, M; Suzuki, K; Morris, K; Pompilus, F; Phillips-Jones, A; Zhou, XOL; Fulci, G; Sule, N; Kremer, BE; Opalinska, J; Mateos, MV; Trudel, S
    View PubMed
  • TRANSPL INFECT DIS 2024 10.1111/tid.14328 QuantiFERON monitor predicts early cytomegalovirus infection and viral burden in allogeneic hematopoietic stem cell transplantation Yoon, E; Shin, S; Choi, S; Jang, JH; Kim, K; Kim, SJ; Kim, WS; Jung, CW; Kang, ES
    View PubMed
  • CANCER RES TREAT 2024 10.4143/crt.2024.074 Nation-Wide Retrospective Analysis of Allogeneic Stem Cell Transplantation in Patients with Multiple Myeloma: A Study from Korean Multiple Myeloma Working Party (KMM1913) Shin, HJ; Kim, D; Kim, K; Min, CK; Lee, JJ; Mun, YC; Lee, WS; Lim, SN; Kim, JS; Moon, JH; Kim, DJ; Bang, SM; Won, JH; Jo, JC; Koh, YI
    View PubMed
  • HAEMATOLOGICA 2024 10.3324/haematol.2023.284238 Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 study Ninkovic, S; Harrison, SJ; Lee, JJ; Murphy, N; Lee, JH; Estell, J; Chen, VM; Horvath, N; Kim, K; Eek, R; Augustson, B; Bang, SM; Huang, SY; Rajagopal, R; Szabo, F; Engeler, D; Butcher, BE; Mollee, P; Durie, B; Chng, WJ; Quach, H
    View PubMed
  • NEW ENGL J MED 2024 10.1056/NEJMoa2405090 Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma Hungria, V; Robak, P; Hus, M; Zherebtsova, V; Ward, C; Ho, PJ; de Almeida, ACR; Hajek, R; Kim, K; Grosicki, S; Sia, H; Bryant, A; de Lacerda, MP; Martinez, GA; Balari, AMS; Sandhu, I; Cerchione, C; Ganly, P; Dimopoulos, M; Fu, CC; Garg, M; Abdallah, A; Oriol, A; Gatt, ME; Cavo, M; Rifkin, R; Fujisaki, T; Mielnik, M; Pirooz, N; Mckeown, A; Mcnamara, S; Zhou, XD; Nichols, M; Lewis, E; Rogers, R; Baig, H; Eccersley, L; Roy-Ghanta, S; Opalinska, J; Mateos, MV
    View PubMed
  • BMC MED RES METHODOL 2024 10.1186/s12874-024-02227-0 The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR) Aoki, N; Chen, PY; Chen, WM; Chng, WJ; Gan, GG; Goh, YT; Hou, J; Huang, J; Kim, K; Lee, JJ; Lu, J; McQuilten, ZK; Min, CK; Moore, E; Oliver, L; Waters, NA; Wellard, C; Wood, EM; Yeh, SP; Spencer, A
    View PubMed
  • J CLIN ONCOL 2024 10.1200/JCO.2024.42.36_suppl.439572 Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) plus bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). Mateos, MV; Robak, P; Hus, M; Xia, ZJ; Zherebtsova, V; Ward, C; Ho, PJ; Hajek, R; Kim, K; Dimopoulos, MA; Cerchione, C; Riccio, A; McKeown, A; Rogers, R; Baig, H; Eccersley, L; Roy-Ghanta, S; Opalinska, J; Hungria, V
    View PubMed
  • CL LYMPH MYELOM LEUK 2024 10.1016/j.clml.2023.10.004 Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study Yi, JH; Lee, JL; Lee, YJ; Kang, HJ; Park, YH; Yuh, YJ; Lim, SN; Kim, HJ; Jung, SH; Lee, JJ; Cho, HJ; Moon, JH; Yhim, HY; Kim, K
    View PubMed
  • J KOREAN MED SCI 2024 10.3346/jkms.2024.39.e5 A Multicenter Analysis of Clinical Features and Long-Term Outcomes of POEMS Syndrome in Korea Kook, HW; Jang, JE; Min, CK; Yoon, DH; Kim, K; Bang, SM; Park, Y; Lee, JH; Yoon, SS; Kim, JS
    View PubMed
  • HEMASPHERE 2024 10.1002/hem3.33 Evaluation of the R2-ISS in real-world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202) Cho, H; Kim, K; Yoon, SE; Jung, SH; Lee, JJ; Moon, JH; Cho, HJ; Lee, HS; Kang, KW; Kim, SY; Eom, HS; Mun, YC; Park, YH; Yoon, SS; Do, YR; Lee, WS; Min, CK; Yoon, DH
    View PubMed
  • ANN HEMATOL 2024 10.1007/s00277-024-05615-0 Real-world outcome of patients with extensively pretreated multiple myeloma who were treated with selinexor and dexamethasone: a Korean multicenter retrospective analysis Yi, JH; Park, SS; Min, CK; Eom, HS; Byun, JM; Koh, Y; Yoon, SS; Lee, JH; Jung, SH; Lee, JJ; Yoon, SE; Woo, SY; Kim, K
    View PubMed
  • CANCER IMAGING 2023 10.1186/s40644-023-00625-z Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation Lee, H; Hyun, SH; Cho, YS; Moon, SH; Choi, JY; Kim, K; Lee, KH
    View PubMed
  • CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2023.06.011 Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis Kawano, Y; Kim, K; Min, CK; Koh, Y; Ishizawa, K; Kim, SH; Ito, S; Tanaka, J; Uchiyama, M; Ishida, T; Kim, JS; Moreau, P; Martin, T; Tada, K; Risse, ML; Suzuki, K
    View PubMed
  • BMC MED IMAGING 2023 10.1186/s12880-023-01054-x Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis Park, YJ; Lee, JH; Kim, D; Choi, JO; Kim, SJ; Kim, K; Choi, JY
    View PubMed
  • ANN HEMATOL 2023 10.1007/s00277-023-05308-0 Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015) Kim, M; Lee, JJ; Min, CK; Lee, JY; Jo, JC; Yoon, SS; Lim, SN; Do, YR; Kim, K; Lee, JH; Yoo, KH; Bae, SH; Yi, JH; Jung, J; Eom, HS; Jung, SH
    View PubMed
  • CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2023.02.009 Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study Fu, WJ; Bang, SM; Huang, HH; Kim, K; Li, W; An, G; Lee, JJ; Cai, Z; Jin, J; Wang, YF; Lin, TL; Chim, CS; Qi, M; Wang, JP; Lu, XL; Song, Y; Jia, B; Yang, X; Liu, WY; Zhou, TY; Yin, L; Li, YA; Zhang, RY; Hou, J; Wang, JX
    View PubMed
  • KOREAN CIRC J 2023 10.4070/kcj.2022.0356 A Novel Transthyretin Gene Mutation in Hereditary Transthyretin Amyloidosis: A Case Series of Met13dup Patients Jeon, K; Kim, D; Park, M; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • SCI REP-UK 2023 10.1038/s41598-023-34653-3 Cluster analysis of autoencoder-extracted FDG PET/CT features identifies multiple myeloma patients with poor prognosis Lee, H; Hyun, SH; Cho, YS; Moon, SH; Choi, JY; Kim, K; Lee, KH
    View PubMed
  • BLOOD CANCER J 2023 10.1038/s41408-023-00797-8 Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study Martin, T; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Casca, F; Mace, S; Risse, ML; Moreau, P
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.952 Cyclophosphamide, Bortezomib, and Dexamethasone Consolidation in Patients with Multiple Myeloma after Stem Cell Transplantation: The KMM130 Study Jung, J; Kim, K; Jung, SH; Yoon, SS; Lee, JH; Kim, JS; Shin, HJ; Bang, SM; Sohn, SK; Suh, C; Yoon, DH; Kong, SY; Min, CK; Eom, HS; Korean Multiple Myeloma Working Party
    View PubMed
  • ANN HEMATOL 2023 10.1007/s00277-023-05090-z Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA Suzuki, K; Wechalekar, AD; Kim, K; Shimazaki, C; Kim, JS; Ikezoe, T; Min, CK; Zhou, FD; Cai, Z; Chen, XN; Iida, S; Katoh, N; Fujisaki, T; Shin, HJ; Tran, N; Qin, X; Vasey, SY; Tromp, B; Weiss, BM; Comenzo, RL; Kastritis, E; Lu, J
    View PubMed
  • CL LYMPH MYELOM LEUK 2023 10.1016/j.clml.2022.10.010 Single Center Experience of Autologous Stem Cell Transplantation in Patients with Systemic Light Chain Amyloidosis in Korea Kim, HR; Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
    View PubMed
  • AM J HEMATOL 2023 10.1002/ajh.26866 Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice Sanchorawala, V; Wechalekar, AD; Kim, K; Schonland, SO; Landau, HJ; Kwok, F; Suzuki, K; Dispenzieri, A; Merlini, G; Comenzo, RL; Cherepanov, D; Hayden, VC; Kumar, A; Labotka, R; Faller, DV; Kastritis, E
    View PubMed
  • NEPHROL DIAL TRANSPL 2023 10.1093/ndt/gfad016 Acute kidney injury in bortezomib-treated patients with multiple myeloma Song, SM; Jeon, J; Jang, HR; Kim, K; Huh, W; Kim, YG; Lee, JE
    View PubMed
  • INT J HEMATOL 2022 10.1007/s12185-022-03525-3 A comprehensive overview of AL amyloidosis disease characteristics accumulated over two decades at a single referral center in Korea Yoon, SE; Kim, D; Choi, JO; Min, JH; Kim, BJ; Kim, JS; Lee, JE; Choi, JY; Jeon, ES; Kim, SJ; Kim, K
    View PubMed
  • INT J HEMATOL 2022 10.1007/s12185-022-03479-6 Real-world toxicity and effectiveness of ixazomib, lenalidomide, and dexamethasone in Korean patients with relapsed and/or refractory multiple myeloma Lee, JH; Kim, SH; Kim, HR; Min, CK; Lee, JJ; Shin, HJ; Jo, JC; Lee, JY; Moon, JH; Kim, K
    View PubMed
  • BLOOD CANCER J 2022 10.1038/s41408-022-00755-w Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party Jung, SH; Kim, K; Yoon, SE; Moon, JH; Kim, D; Kim, HJ; Kim, MK; Ha Kim, K; Lee, HJ; Lee, JH; Kim, SH; Yoo, KH; Lee, JH; Lee, JJ
    View PubMed
  • J HEMATOL ONCOL 2022 10.1186/s13045-022-01374-5 Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease Byun, JM; Min, CK; Kim, K; Bang, SM; Lee, JJ; Kim, JS; Yoon, SS; Koh, Y
    View PubMed
  • ANN LAB MED 2022 10.3343/alm.2022.42.5.558 Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma Kim, HY; Yoo, IY; Lim, DJ; Kim, HJ; Kim, SH; Yoon, SE; Kim, SJ; Cho, D; Kim, K
    View PubMed
  • BONE MARROW TRANSPL 2022 10.1038/s41409-022-01818-z Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909) Jung, SH; Min, CK; Lee, JH; Mun, YC; Bang, SM; Yoon, DH; Lee, HS; Kim, K; Lee, JJ
    View PubMed
  • BLOOD ADV 2022 10.1182/bloodadvances.2021006713 Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma Martin, T; Mikhael, J; Hajek, R; Kim, K; Suzuki, K; Hulin, C; Garg, M; Quach, H; Sia, H; George, A; Konstantinova, T; Risse, ML; Asset, G; Mace, S; van de Velde, H; Moreau, P
    View PubMed
  • FRONT ONCOL 2022 10.3389/fonc.2022.959949 Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study) Song, GY; Jung, SH; Kim, JS; Eom, HS; Moon, JH; Yhim, HY; Kim, K; Min, CK; Lee, JJ; Korean Multiple Myeloma Working Party
    View PubMed
  • CL LYMPH MYELOM LEUK 2022 10.1016/j.clml.2022.04.005 Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis Sunami, K; Ikeda, T; Huang, SY; Wang, MC; Koh, Y; Min, CK; Yeh, SP; Matsumoto, M; Uchiyama, M; Iyama, S; Shimazaki, C; Lee, JH; Kim, K; Kaneko, H; Kim, JS; Lin, TL; Campana, F; Tada, K; Iida, S; Suzuki, K
    View PubMed
  • AMYLOID 2022 10.1080/13506129.2022.2082866 Generalised autonomic failure as a prognostic factor in systemic light-chain (AL) amyloidosis Kwon, S; Jeong, WK; Park, JH; Kim, J; Cho, EB; Seok, JM; Kim, SJ; Kim, K; Jeon, ES; Min, JH; Kim, BJ
    View PubMed
  • FRONT CARDIOVASC MED 2022 10.3389/fcvm.2022.904878 Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis Bak, M; Kim, D; Choi, JO; Kim, K; Kim, SJ; Jeon, ES
    View PubMed
  • INT J HEMATOL 2022 10.1007/s12185-022-03378-w Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis Kim, K; Min, CK; Koh, Y; Ishizawa, K; Kim, SH; Ito, S; Tanaka, J; Uchiyama, M; Kawano, Y; Kim, JS; Moreau, P; Martin, T; Dong, Y; Risse, ML; Suzuki, K
    View PubMed
  • INT J HEMATOL 2022 10.1007/s12185-022-03332-w Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805) Kim, K; Kim, JS; Yoon, SS; Yoon, DH; Eom, HS; Lee, JJ; Yim, HW; Park, M; Lee, H; Min, CK
    View PubMed
  • ANN HEMATOL 2022 10.1007/s00277-022-04776-0 Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma Chu, TH; Jung, SH; Kim, K; Lee, JH; Mun, YC; Bang, SM; Yoon, DH; Lee, HS; Min, CK; Lee, JJ
    View PubMed
  • AM J HEMATOL 2022 10.1002/ajh.26536 Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone +/- daratumumab: Results from the ANDROMEDA study Sanchorawala, V; Palladini, G; Minnema, MC; Jaccard, A; Lee, HC; Gibbs, S; Mollee, P; Venner, C; Lu, J; Schonland, S; Gatt, M; Suzuki, K; Kim, K; Cibeira, MT; Beksac, M; Libby, E; Valent, J; Hungria, V; Wong, SW; Rosenzweig, M; Bumma, N; Chauveau, D; Gries, KS; Fastenau, J; Tran, NP; Qin, X; Vasey, SY; Weiss, BM; Vermeulen, J; Ho, KF; Merlini, G; Comenzo, RL; Kastritis, E; Wechalekar, AD
    View PubMed
  • CURR PROB CANCER 2022 10.1016/j.currproblcancer.2021.100788 Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features Yoo, KH; Yoon, DH; Kang, HJ; Lee, WS; Kim, K; Kim, JS; Kim, JA; Kim, SH; Kwak, JY; Kim, YS; Min, CK; Lee, JJ; Yoon, SS; Suh, C; Baz, R; Lee, JH
    View PubMed
  • CURR PROB CANCER 2022 10.1016/j.currproblcancer.2021.100786 Limite d b enefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea Byun, JM; Kim, SA; Koh, Y; Shin, DY; Kwon, JH; Kim, JS; Kim, K; Min, CK; Eom, HS; Lee, JJ; Bang, SM; Yoon, SS
    View PubMed
  • JACC CARDIOVASC IMAGING 2021 2021 Association of Left Ventricular Global Longitudinal Strain With Cardiac Amyloid Load in Light Chain Amyloidosis Kim1, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • LANCET 2021 10.1016/S0140-6736(21)00592-4 2021 Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial Moreau1, P; Dimopoulos, MA; Mikhael, J; Yong, K; Capra, M; Facon, T; Hajek, R; Spicka, I; Baker, R; Kim, K; Martinez, G; Min, CK; Pour, L; Leleu, X; Oriol, A; Koh, Y; Suzuki, K; Risse, ML; Asset, G; Mace, S; Martin, T
    View PubMed
  • LEUKEMIA 2021 10.1038/s41375-021-01317-y 2021 A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis Dispenzieri1, A; Kastritis, E; Wechalekar, AD; Schonland, SO; Kim, K; Sanchorawala, V; Landau, HJ; Kwok, F; Suzuki, K; Comenzo, RL; Berg, D; Liu, GH; Kumar, A; Faller, DV; Merlini, G
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17541 2021 Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy Quach1, H; Nooka, A; Samoylova, O; Venner, CP; Kim, K; Facon, T; Spencer, A; Usmani, SZ; Grosicki, S; Suzuki, K; Delimpasi, S; Weisel, K; Obreja, M; Zahlten-Kumeli, A; Mateos, MV
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 2021 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed
  • J CLIN MED 2021 10.3390/jcm10071376 2021 Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active Mycobacterium tuberculosis Infections in Tertiary Care Setting? Jung1, J; Jhun, BW; Jeong, M; Yoon, SJ; Huh, HJ; Jung, CW; Kim, K; Park, JB; Kim, DJ; Huh, W; Jang, HR; Kim, YH; Hong, SN; Chung, DR; Kang, ES
    View PubMed
  • J CANCER 2021 10.7150/jca.55553 2021 Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis Lee1, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ
    View PubMed
  • SUPPORT CARE CANCER 2021 10.1007/s00520-021-06017-y 2021 Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma Kim1, SJ; Kang, D; Park, Y; Mun, YC; Kim, K; Kim, JS; Min, CK; Cho, J
    View PubMed
  • ANN HEMATOL 2021 10.1007/s00277-021-04405-2 2021 Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study Iida1, S; Ishikawa, T; Min, CK; Kim, K; Yeh, SP; Usmani, SZ; Mateos, MV; Nahi, H; Heuck, C; Qin, X; Parasrampuria, DA; Gries, KS; Qi, M; Bahlis, N; Ito, S
    View PubMed
  • ANN HEMATOL 2021 10.1007/s00277-021-04407-0 2021 Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial Lee1, JH; Park, Y; Kang, KW; Lee, JJ; Lee, HS; Eom, HS; Do, YR; Kim, JS; Yoon, SS; Shin, DY; Koh, Y; Kim, KH; Lee, WS; Jo, JC; Lee, YJ; Lee, JY; Kim, DS; Shim, H; Chang, MH; Kim, SH; Min, CK
    View PubMed
  • BLOOD CANCER J 2021 10.1038/s41408-021-00577-2 Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-18-FDG PET/CT Cho, HJ; Jung, SH; Jo, JC; Lee, YJ; Yoon, SE; Park, SS; Kim, DY; Shin, HJ; Mun, YC; Yi, JH; Kim, HJ; Kim, DJ; Lee, HS; Bae, SH; Hong, CM; Jeong, SY; Min, JJ; Sohn, SK; Min, CK; Kim, K; Lee, JJ; Moon, JH
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17898 Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma Jung, SH; Lee, JJ; Song, GY; Lee, HS; Kim, SJ; Yoon, SE; Kim, K
    View PubMed
  • ANAL CHEM 2021 10.1021/acs.analchem.1c01722 tipNrich: A Tip-Based N-Terminal Proteome Enrichment Method Lee, S; Ju, S; Kim, SJ; Choi, JO; Kim, K; Kim, D; Jeon, ES; Lee, C
    View PubMed
  • ESC HEART FAIL 2021 10.1002/ehf2.13604 Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis Kim, D; Choi, JO; Kim, K; Kim, SJ; Kim, JS; Jeon, ES
    View PubMed
  • INT J HEMATOL 2021 10.1007/s12185-021-03204-9 Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial Suzuki, K; Min, CK; Kim, K; Lee, JJ; Shibayama, H; Ko, PS; Huang, SY; Li, SS; Ding, BF; Khurana, M; Iida, S
    View PubMed
  • J CLIN APHERESIS 2021 10.1002/jca.21924 Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34(+) cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation Kim, SM; Kim, HY; Kim, SJ; Jang, JH; Kim, K; Kim, WS; Jung, CW; Cho, D; Kang, ES
    View PubMed
  • NEW ENGL J MED 2021 10.1056/NEJMoa2028631 Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis Kastritis, E; Palladini, G; Minnema, MC; Wechalekar, AD; Jaccard, A; Lee, HC; Sanchorawala, V; Gibbs, S; Mollee, P; Venner, CP; Lu, J; Schonland, S; Gatt, ME; Suzuki, K; Kim, K; Cibeira, MT; Beksac, M; Libby, E; Valent, J; Hungria, V; Wong, SW; Rosenzweig, M; Bumma, N; Huart, A; Dimopoulos, MA; Bhutani, D; Waxman, AJ; Goodman, SA; Zonder, JA; Lam, S; Song, K; Hansen, T; Manier, S; Roeloffzen, W; Jamroziak, K; Kwok, F; Shimazaki, C; Kim, JS; Crusoe, E; Ahmadi, T; Tran, NP; Qin, X; Vasey, SY; Tromp, B; Schecter, JM; Weiss, BM; Zhuang, SH; Vermeulen, J; Merlini, G; Comenzo, RL
    View PubMed
  • BRIT J HAEMATOL 2020 10.1111/bjh.17071 2020 Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy Park1, SS; Byun, JM; Yoon, SS; Kim, K; Jung, SH; Lee, JJ; Min, CK
    View PubMed
  • BLOOD CANCER J 2020 10.1038/s41408-020-00375-2 2020 Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma a cytogenetic subgroup analysis of POLLUX Kaufman1, JL; Dimopoulos, MA; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Sutherland, HJ; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis, NJ; Chari, A; O'Rourke, L; Trivedi, S; Casneuf, T; Krevvata, M; Ukropec, J; Kobos, R; Avet-Loiseau, H; Usmani, SZ; San-Miguel, J
    View PubMed
  • LEUKEMIA 2020 10.1038/s41375-020-01060-w 2020 Clinical features and survival outcomes in IgD myeloma a study by Asia Myeloma Network (AMN) Liu1, J; Hu, XX; Jia, YC; Lu, J; Lee, JH; Kim, K; Chen, WM; Liu, AJ; Liu, Y; Chen, Q; Zhang, CY; Suh, C; Kim, MK; Zhou, F; Chng, WJ; Kumar, SK; Durie, B; Hou, J; Fu, WJ; Du, J
    View PubMed
  • INT J HEMATOL 2020 10.1007/s12185-020-02988-6 2020 Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone Lee1, HS; Kim, K; Lee, JJ; Yoon, SS; Bang, SM; Kim, JS; Eom, HS; Yoon, DH; Lee, YJ; Shin, HJ; Park, Y; Jo, JC; Lee, WS; Do, YR; Mun, YC; Lee, MH; Kim, HJ; Kim, SH; Kim, MK; Lim, SN; Park, SK; Yi, JH; Lee, JH; Min, CK
    View PubMed
  • PATIENT EDUC COUNS 2020 10.1016/j.pec.2020.03.007 2020 Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners Kim1, IR; Jang, SY; Shin, HS; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Kim, SJ; Kim, K; Kim, WS; Lee, CH; Kang, D; Cho, J
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07317-y 2020 Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma Song1, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ
    View PubMed
  • INT J HEMATOL 2020 10.1007/s12185-020-02869-y 2020 Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea the KMM1807 study Jung1, J; Choi, YS; Lee, JH; Lee, WS; Kim, SH; Park, Y; Lee, SS; Do, YR; Jo, JC; Lee, JJ; Kim, JS; Shin, HJ; Shin, DY; Yoon, SS; Min, CK; Kim, K; Eom, HS
    View PubMed
  • CLIN CANCER RES 2020 10.1158/1078-0432.CCR-19-0694 2020 Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion Ryu1, D; Kim, SJ; Hong, Y; Jo, A; Kim, N; Kim, HJ; Lee, HO; Kim, K; Park, WY
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-019-03904-7 2020 The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) Jo1, JC; Lee, HS; Kim, K; Lee, JJ; Yoon, SS; Bang, SM; Kim, JS; Eom, HS; Yoon, DH; Lee, Y; Shin, HJ; Park, Y; Lee, WS; Do, YR; Mun, YC; Lee, MH; Kim, HJ; Kim, SH; Kim, MK; Lim, SN; Cho, SH; Park, SK; Yi, JH; Lee, JH; Kim, J; Min, CK
    View PubMed
  • J AM COLL CARDIOL 2020 10.1016/j.jacc.2019.11.045 2020 Prognostic Value of the Index of Microcirculatory Resistance Over Serum Biomarkers in Cardiac Amyloidosis Choi1, KH; Lee, JM; Kim, SR; Kim, D; Choi, JO; Kim, SJ; Kim, K; Kim, JS; Koo, BK; Jeon, ES
    View PubMed
  • CLIN LYMPHOMA MYELOMA LEUK 2020 10.1016/j.clml.2019.10.017 2020 Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study Jung1, KS; Kim, K; Kim, HJ; Kim, SH; Lee, JO; Kim, JS; Lee, JJ; Eom, HS; Min, CK; Shin, HJ
    View PubMed
  • MEDICINE 2020 10.1097/MD.0000000000018905 2020 Tc-99m-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis Potential clinical implications Lee1, JH; Kim, K; Choi, JO; Kim, SJ; Jeon, ES; Choi, JY
    View PubMed
  • ANN LAB MED 2020 10.3343/alm.2020.40.1.88 2020 Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults Choi1, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES
    View PubMed
  • AM J HEMATOL 2020 10.1002/ajh.25726 2020 Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) Lee1, HS; Kim, K; Kim, SJ; Lee, JJ; Kim, I; Kim, JS; Eom, HS; Yoon, DH; Suh, C; Shin, HJ; Mun, YC; Kim, MK; Lim, SN; Choi, CW; Kang, HJ; Yoon, SS; Min, CK
    View PubMed
  • LEUKEMIA 2020 10.1038/s41375-020-0711-6 2020 Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study Bahlis1, NJ; Dimopoulos, MA; White, DJ; Benboubker, L; Cook, G; Leiba, M; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Krevvata, M; Chiu, C; Qin, X; Okonkwo, L; Trivedi, S; Ukropec, J; Qi, M; San-Miguel, J
    View PubMed
  • LEUKEMIA 2020 10.1038/s41375-019-0539-0 2020 A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Facon1, T; Dimopoulos, MA; Meuleman, N; Belch, A; Mohty, M; Chen, WM; Kim, K; Zamagni, E; Rodriguez-Otero, P; Renwick, W; Rose, C; Tempescul, A; Boyle, E; Manier, S; Attal, M; Moreau, P; Macro, M; Leleu, X; Chretien, ML; Ludwig, H; Guo, S; Sturniolo, M; Tinel, A; Monzini, MS; Costa, B; Houck, V; Hulin, C; Mary, JY
    View PubMed
  • IMMUNOL LETT 2019 10.1016/j.imlet.2019.10.005 2019 A combination regimen of low-dose bortezomib and rapamycin prolonged the graft survival in a murine allogeneic islet transplantation model Hong1, SH; Kim, K; Shin, JS; Chung, H; Park, CG
    View PubMed
  • BONE MARROW TRANSPL 2019 10.1038/s41409-019-0629-7 2019 Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma Lee1, YJ; Moon, JH; Sohn, SK; Kim, SJ; Jung, SH; Lee, JJ; Jo, JC; Shin, HJ; Lee, WS; Lee, JH; Bae, SH; Kim, MK; Lee, HS; Kim, K; Min, CK
    View PubMed
  • Blood Cancer J 2019 10.1038/s41408-019-0245-1 2019 Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network Soekojo1, CY; Kim, K; Huang, SY; Chim, CS; Takezako, N; Asaoku, H; Kimura, H; Kosugi, H; Sakamoto, J; Gopalakrishnan, SK; Nagarajan, C; Wei, Y; Moorakonda, R; Lee, SL; Lee, JJ; Yoon, SS; Kim, JS; Min, CK; Lee, JH; Durie, B; Chng, WJ
    View PubMed
  • J CLIN APHERESIS 2019 10.1002/jca.21734 2019 Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma Park1, Y; Kim, DS; Jeon, MJ; Lee, BH; Yu, ES; Kang, KW; Lee, SR; Sung, HJ; Nam, MH; Yoon, SY; Choi, CW; Kang, ES; Cho, D; Kim, K; Kim, BS; Kim, DW; Kim, SJ
    View PubMed
  • EUR J CANCER CARE 2019 10.1111/ecc.13089 2019 Influence of time lapse after cancer diagnosis on the association between unmet needs and quality of life in family caregivers of Korean cancer patients Shin1, J; Ko, H; Lee, JW; Kim, K; Song, YM
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-48513-6 2019 Prognostic values of novel biomarkers in patients with AL amyloidosis Kim1, D; Lee, G; Choi, JO; Kim, K; Kim, S; Ju, ES; Jeon, ES
    View PubMed
  • BIOL BLOOD MARROW TR 2019 10.1016/j.bbmt.2019.03.016 2019 A Phase I/II Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study Park1, SS; Kim, K; Kim, SJ; Lee, JH; Yoon, SS; Mun, YC; Lee, JJ; Eom, HS; Kim, JS; Min, CK
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-44245-9 2019 Associations of Electrocardiographic Parameters with Left Ventricular Longitudinal Strain and Prognosis in Cardiac Light Chain Amyloidosis Kim1, D; Lee, GY; Choi, JO; Kim, K; Kim, SJ; Jeon, ES
    View PubMed
  • ANN HEMATOL 2019 10.1007/s00277-019-03602-4 2019 Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries Hungria1, VTM; Lee, JH; Maiolino, A; Crusoe, ED; Martinez, G; Bittencourt, R; Duarte, GO; Fantl, DB; Navarro, JR; Conte, G; Gomez-Almaguer, D; Ruiz-Arguelles, GJ; Kim, K; Shimizu, K; Chen, WM; Huang, SY; Chng, WJ; Chim, CS; Nawarawong, W; Durie, B
    View PubMed
  • Oncoimmunology 2019 10.1080/2162402X.2018.1544442 2019 PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer Angell1, HK; Lee, J; Kim, KM; Kim, K; Kim, ST; Park, SH; Kang, WK; Sharpe, A; Ogden, J; Davenport, A; Hodgson, DR; Barrett, JC; Kilgour, E
    View PubMed
  • INT J HEMATOL 2019 10.1007/s12185-018-2540-1 2019 Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone Shin1, J; Lee, JJ; Kim, K; Min, CK; Lee, JO; Suh, C; Kim, JS; Lee, YJ; Yoon, SS; Jo, JC; Lee, HS; Bang, SM; Lee, JO; Bang, SM; Lee, JJ; Kim, K; Min, CK; Suh, C; Yoon, DH; Kim, JS; Lee, YJ; Moon, JH; Yoon, SS; Kim, I; Jo, JC; Lee, HS; Park, SK; Shin, HJ; Kim, MK; Mun, YC; Lee, MH; Park, Y; Eom, HS; Kim, HJ; Im, SN; Kim, SH; Do, YR; Lee, WS; Cho, SH; Yi, JH; Lee, JH
    View PubMed
  • JPN J CLIN ONCOL 2019 10.1093/jjco/hyy177 2019 Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice Park1, SS; Eom, HS; Kim, JS; Koh, Y; Choi, CW; Lee, JJ; Kim, K; Suh, C; Lee, JH; Min, CK
    View PubMed
  • ANN LAB MED 2019 10.3343/alm.2019.39.1.96 2019 First Case of Plasma Cell Myeloma With Brown Tumor Features Unrelated to Hyperparathyroidism Kim1, H; Kim, K; Cho, SR; Kim, HJ; Kim, SH
    View PubMed
  • J CLIN MICROBIOL 2018 10.1128/JCM.00438-18 2018 Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients Ryu1, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES
    View PubMed
  • HAEMATOL-HEMATOL J 2018 10.3324/haematol.2018.194282 2018 Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX Dimopoulos1, MA; San-Miguel, J; Belch, A; White, D; Benboubker, L; Cook, G; Leiba, M; Morton, J; Ho, PJ; Kim, K; Takezako, N; Moreau, P; Kaufman, JL; Sutherland, HJ; Lalancette, M; Magen, H; Iida, S; Kim, JS; Prince, HM; Cochrane, T; Oriol, A; Bahlis, NJ; Chari, A; O'Rourke, L; Wu, K; Schecter, JM; Casneuf, T; Chiu, C; Soong, D; Sasser, AK; Khokhar, NZ; Avet-Loiseau, H; Usmani, SZ
    View PubMed
  • ACTA HAEMATOL-BASEL 2018 10.1159/000490488 2018 The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma Lee1, GW; Park, SW; Go, SI; Kim, HG; Kim, MK; Min, CK; Kwak, JY; Bae, SB; Yoon, SS; Lee, JJ; Kim, KH; Nam, SH; Mun, YC; Kim, HJ; Bae, SH; Shin, HJ; Lee, JH; Park, JS; Jeong, SH; Lee, MH; Lee, HS; Park, KW; Lee, WS; Lee, SM; Lee, JO; Hyun, MS; Jo, DY; Lim, SN; Lee, JH; Kim, H; Cho, DY; Do, YR; Kim, JA; Park, SK; Kim, JS; Kim, SJ; Yi, HG; Moon, JH; Choi, CW; Kim, SH; Kim, BS; Park, MR; Shim, H; Song, MK; Kim, Y; Kim, K
    View PubMed
  • LEUKEMIA LYMPHOMA 2018 10.1080/10428194.2018.1427858 2018 Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop Tan1, D; Lee, JH; Chen, WM; Shimizu, K; Hou, J; Suzuki, K; Nawarawong, W; Huang, SY; Chim, CS; Kim, K; Kumar, L; Malhotra, P; Chng, WJ; Durie, B
    View PubMed
  • GENOME RES 2018 10.1101/gr.228080.117 2018 Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data Fan1, J; Lee, HO; Lee, S; Ryu, DE; Lee, S; Xue, C; Kim, SJ; Kim, K; Barkas, N; Park, PJ; Park, WY; Kharchenko, PV
    View PubMed
  • BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5 2018 Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J
    View PubMed
  • BRIT J HAEMATOL 2018 10.1111/bjh.14701 2018 A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System Jung1, SH; Kim, K; Kim, JS; Kim, SJ; Cheong, JW; Kim, SJ; Ahn, JS; Ahn, SY; Yang, DH; Kim, HJ; Lee, JJ
    View PubMed
  • BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.01.004 2018 Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) Jung1, SH; Lee, JJ; Kim, JS; Min, CK; Kim, K; Choi, Y; Eom, HS; Joo, YD; Kim, SH; Kwak, JY; Kang, HJ; Lee, JH; Lee, HS; Mun, YC; Moon, JH; Sohn, SK; Park, SK; Park, Y; Shin, HJ; Yoon, SS
    View PubMed
  • KOREAN J RADIOL 2018 10.3348/kjr.2018.19.3.481 2018 Prognostic Value of Baseline F-18-Fluorodeoxyglucose PET/CT in Patients with Multiple Myeloma: A Multicenter Cohort Study Moon1, SH; Choi, WH; Yoo, IR; Lee, SJ; Paeng, JC; Jeong, SY; Lee, SW; Kim, K; Choi, JY
    View PubMed
  • ANN LAB MED 2018 10.3343/alm.2018.38.3.196 2018 Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience Jung1, HA; Jang, MA; Kim, K; Kim, SH
    View PubMed
  • PROTEOM CLIN APPL 2018 10.1002/prca.201700106 2018 Development and Validation of Mass Spectrometry-Based Targeted Analysis for Amyloid Proteins Park1, J; Lee, GY; Choi, JO; Jeon, ES; Kim, K; Kim, JS; Lee, SY
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 2018 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • AM J HEMATOL 2017 10.1002/ajh.24891 2017 Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy Cho1, H; Yoon, DH; Lee, JB; Kim, SY; Moon, JH; Do, YR; Lee, JH; Park, Y; Lee, HS; Eom, HS; Shin, HJ; Min, CK; Kim, JS; Jo, JC; Kang, HJ; Mun, YC; Lee, WS; Lee, JJ; Suh, C; Kim, K
    View PubMed
  • JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120 2017 Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy Park1, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K
    View PubMed
  • LEUKEMIA 2017 10.1038/leu.2017.138 2017 Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study Kumar1, SK; Dimopoulos, MA; Kastritis, E; Terpos, E; Nahi, H; Goldschmidt, H; Hillengass, J; Leleu, X; Beksac, M; Alsina, M; Oriol, A; Cavo, M; Ocio, EM; Mateos, MV; O'Donnell, EK; Vij, R; Lokhorst, HM; van de Donk, NWCJ; Min, C; Mark, T; Turesson, I; Hansson, M; Ludwig, H; Jagannath, S; Delforge, M; Kyriakou, C; Hari, P; Mellqvist, U; Usmani, SZ; Dytfeld, D; Badros, AZ; Moreau, P; Kim, K; Otero, PR; Lee, JH; Shustik, C; Waller, D; Chng, WJ; Ozaki, S; Lee, JJ; de la Rubia, J; Eom, HS; Rosinol, L; Lahuerta, JJ; Sureda, A; Kim, JS; Durie, BGM
    View PubMed
  • Clin Transl Oncol 2017 10.1007/s12094-017-1662-x 2017 Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma Cho1, J; Kim, SY; Kim, YJ; Sim, MH; Kim, ST; Kim, NKD; Kim, K; Park, W; Kim, JH; Jang, KT; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18535 2017 The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160) Jung1, SH; Lee, JJ; Kim, K; Suh, C; Yoon, DH; Min, CK; Sohn, SK; Choi, CW; Lee, HS; Kim, HJ; Shin, HJ; Bang, SM; Yoon, SS; Park, SK; Yhim, HY; Kim, MK; Jo, JC; Mun, YC; Lee, JH; Kim, JS
    View PubMed
  • Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25. 2017 Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.
    View PubMed
  • Br J Haematol. 2017 Mar;176(5):743-749. doi: 10.1111/bjh.14465. Epub 2017 Jan 20. 2017 Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial Lu J11, Lee JH2, Huang SY3, Qiu L4, Lee JJ5, Liu T6, Yoon SS7, Kim K8, Shen ZX9, Eom HS10, Chen WM11, Min CK12, Kim HJ13, Lee JO14, Kwak JY15, Yiu W16, Chen G16, Ervin-Haynes A16, Hulin C17, Facon T18.
    View PubMed
  • Cancer Med. 2017 Jan;6(1):100-108. doi: 10.1002/cam4.970. Epub 2016 Dec 1. 2017 Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study Kwon J11, Min CK2, Kim K3, Han JJ4, Moon JH5, Kang HJ6, Eom HS7, Kim MK8, Kim HJ9, Yoon DH10, Lee JO11, Lee WS12, Lee JH13, Lee JJ14, Choi YS15, Kim SH16, Yoon SS17.
    View PubMed
  • J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7. 2016 Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.
    View PubMed
  • Oncotarget. 2016 Oct 18;7(42):68350-68359. doi: 10.18632/oncotarget.12029. 2016 Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis Kim SJ11, Shin HT2, Lee HO2, Kim NK2, Yun JW2, Hwang JH3, Kim K1, Park WY2.
    View PubMed
  • Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988. 2016 Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.
    View PubMed
  • BMC Cancer. 2016 Aug 8;16:613. doi: 10.1186/s12885-016-2645-y. 2016 Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen Jung SH11, Cho MS1, Kim HK2, Kim SJ2, Kim K3, Cheong JW4, Kim SJ4, Kim JS4, Ahn JS1, Kim YK1, Yang DH1, Kim HJ1, Lee JJ5; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Oncotarget. 2016 Jul 26;7(30):47127-47133. doi: 10.18632/oncotarget.9478. 2016 Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker Ryu D11,2, Kim HJ3, Joung JG1, Lee HO1,4, Bae JS1, Kim SJ5, Kim H5, Park WY1,2,4, Kim K5.
    View PubMed
  • Ann Hematol. 2016 May;95(6):911-9. doi: 10.1007/s00277-016-2660-8. Epub 2016 Apr 6. 2016 The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea Lee HS11, Min CK2, Lee JJ3, Kim K4, Kim SJ4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13, Lee MH14
    View PubMed
  • J Infect. 2016 Feb;72(2):233-9. doi: 10.1016/j.jinf.2015.10.014. Epub 2015 Nov 26. 2016 Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer Ko JH11, Peck KR2, Lee JY1, Cho SY1, Ha YE1, Kang CI1, Chung DR1, Kim K3, Kang ES4, Song JH1.
    View PubMed
  • Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10. 2016 Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis Lim SH11, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.
    View PubMed
  • Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658. 2015 Iron deficient erythropoiesis might play key role in development of anemia in cancer patients Park S11, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.
    View PubMed
  • J Clin Lab Anal. 2015 Nov;29(6):505-10. doi: 10.1002/jcla.21801. Epub 2014 Oct 2. 2015 Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma Shin SY11, Lee ST1, Kim HJ1, Kim SJ2, Kim K2, Kang ES1, Kim SH1.
    View PubMed
  • Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12. 2015 Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy Lee JY11, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.
    View PubMed
  • Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26. 2015 Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma Park S11, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.
    View PubMed
  • Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25. 2015 KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.
    View PubMed
  • J Hematol Oncol. 2015 Sep 4;8:103. doi: 10.1186/s13045-015-0198-1. 2015 Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study Gupta N11, Goh YT2, Min CK3, Lee JH4, Kim K5, Wong RS6, Chim CS7, Hanley MJ8, Yang H9, Venkatakrishnan K10, Hui AM11, Esseltine DL12, Chng WJ13,14.
    View PubMed
  • Korean J Intern Med. 2015 Sep;30(5):675-83. doi: 10.3904/kjim.2015.30.5.675. Epub 2015 Aug 28. 2015 The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea Kim C11, Lee HS1, Min CK2, Lee JJ3, Kim K4, Yoon DH5, Eom HS6, Lee H6, Lee WS7, Shin HJ8, Lee JH9, Park Y10, Jo JC11, Do YR12, Mun YC13.
    View PubMed
  • Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. 2015 Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia Kim DY1, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology.
    View PubMed
  • Korean J Intern Med. 2015 Jul;30(4):496-505. doi: 10.3904/kjim.2015.30.4.496. Epub 2015 Jun 29. 2015 Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience Lim AY11, Lee JH1, Jung KS1, Gwag HB1, Kim do H1, Kim SJ1, Lee GY1, Kim JS2, Kim HJ3, Lee SY3, Lee JE1, Jeon ES1, Kim K1.
    View PubMed
  • Anticancer Res. 2015 May;35(5):3081-9. 2015 Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome Hong JY11, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.
    View PubMed
  • Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35. doi: 10.1016/j.clml.2014.12.007. Epub 2014 Dec 12. 2015 The t(11;14)(q13;q32) Trans location as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma Shin HJ11, Kim K2, Lee JJ3, Song MK1, Lee EY4, Park SH4, Kim SH5, Jang MA5, Kim SJ6, Chung JS1.
    View PubMed
  • Ann Hum Genet. 2015 Mar;79(2):99-107. doi: 10.1111/ahg.12101. Epub 2015 Jan 23. 2015 Asp58Ala is the Predominant Mutation of the TTR Gene in Korean Patients with Hereditary Transthyretin-Related Amyloidosis Jang MA11, Lee GY, Kim K, Kim SJ, Kim JS, Lee SY, Kim HJ, Jeon ES.
    View PubMed
  • Amyloid. 2014 Dec;21(4):261-6. doi: 10.3109/13506129.2014.960560. Epub 2014 Sep 24. 2014 Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis Lee JY11, Lim SH, Kim SJ, Lee GY, Lee JE, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.
    View PubMed
  • Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31. 2014 Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience Lee KH11, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
    View PubMed
  • Eur J Haematol. 2014 Nov;93(5):414-21. doi: 10.1111/ejh.12377. Epub 2014 Jun 14. 2014 Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma Shin HJ11, Kim K, Lee JW, Song MK, Lee JJ, Lee HS, Lee WS, Kim SJ, Chung JS.
    View PubMed
  • Support Care Cancer. 2014 Oct;22(10):2669-75. doi: 10.1007/s00520-014-2256-6. Epub 2014 Apr 26. 2014 Impact of dose modification on intravenous Bortezomib-induced peripheral neuropathy in multiple myeloma patients Cho J11, Kang D, Lee JY, Kim K, Kim SJ.
    View PubMed
  • Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7. 2014 Spinal cord compression in multiple myeloma: a single center experience Jung HA11, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.
    View PubMed
  • Ann Hematol. 2014 Sep;93(9):1571-7. doi: 10.1007/s00277-014-2067-3. Epub 2014 Apr 12. 2014 Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study Ahn SY11, Jung SH, Joo YD, Lee WS, Lee SM, Choi CW, Kim SJ, Kim K, Lee JJ; Korean Multiple Myeloma Working Party.
    View PubMed
  • Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27. 2014 Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Oh S11, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Acta Haematol. 2014;132(2):226-32. 2014 Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation Chang WJ1, Kang ES, Lee ST, Kim SH, Kim DW, Kim SJ, Kim K.
    View PubMed
  • Ann Hematol. 2014 Aug;93(8):1353-61. doi: 10.1007/s00277-014-2057-5. Epub 2014 Mar 27. 2014 Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Oh S11, Koo DH, Kwon MJ, Kim K, Suh C, Min CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, Kim JS, Sohn SK, Joo YD, Eom HS, Kim SH, Kim YS, Kim C, Mun YC, Kim H, Lee DS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Anticancer Res. 2014 Aug;34(8):4299-306. 2014 Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement Park S11, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
    View PubMed
  • Am J Hematol. 2014 Jul;89(7):751-6. doi: 10.1002/ajh.23731. Epub 2014 Apr 26. 2014 Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study Kim K11, Lee JH, Kim JS, Min CK, Yoon SS, Shimizu K, Chou T, Kosugi H, Suzuki K, Chen W, Hou J, Lu J, Huang XJ, Huang SY, Chng WJ, Tan D, Teoh G, Chim CS, Nawarawong W, Siritanaratkul N, Durie BG.
    View PubMed
  • Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10. 2014 Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma Kim SM11, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
    View PubMed
  • Biomed Res Int. 2014;2014:253243. doi: 10.1155/2014/253243. Epub 2014 Jun 4. 2014 Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea Lee HS11, Kim K2, Yoon DH3, Kim JS4, Bang SM5, Lee JO5, Eom HS6, Lee H6, Kim I7, Lee WS8, Bae SH9, Kim SH10, Lee MH11, Do YR12, Lee JH13, Hong J13, Shin HJ14, Lee JH15, Mun YC16, Min CK17.
    View PubMed
  • Mayo Clin Proc.?2014 Jun;89(6):781-9. doi: 10.1016/j.mayocp.2014.01.013. Epub 2014 Apr 3. 2014 Cardiac Amyloidosis Without Increased Left Ventricular Wall Thickness Lee GY11,?Kim K2,?Choi JO1,?Kim SJ2,?Kim JS3,?Choe YH4,?Grogan MA5,?Jeon ES6.
    View PubMed
  • Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26. 2014 Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients Park S11, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.
    View PubMed
  • Ann Hematol. 2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19. 2014 Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts Seo JY11, Lee KO, Kim SH, Kim K, Jung CW, Jang JH, Kim HJ.
    View PubMed
  • Br J Haematol. 2014 Mar;164(5):745-8. doi: 10.1111/bjh.12670. Epub 2013 Nov 18. 2014 Central nervous system multiple myeloma: a different cytogenetic profile Chang WJ11, Kim SJ, Kim K.
    View PubMed
  • Anticancer Res. 2014 Feb;34(2):1037-45. 2014 Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia Jung HA11, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.
    View PubMed
  • Ann Hematol. 2014 Jan;93(1):113-21. doi: 10.1007/s00277-013-1893-z. Epub 2013 Sep 12. 2014 Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients Kim K11, Kim SJ, Voelter V, Suh C, Yoon SS, Lee JJ, Kwak JY, Ryoo HM, Kim YS, Moon JH, Park SK, Kim SH, Mun YC, Kim JS, Eom HS, Jo DY, Jun HJ, Kim KH, Lee JO, Lee JH, Min CK; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16. 2014 DCEP for relapsed or refractory multiple myeloma after therapy with novel agents Park S11, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.
    View PubMed
  • Amyloid. 2013 Dec;20(4):204-11. doi: 10.3109/13506129.2013.824417. Epub 2013 Aug 5. 2013 Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea Kim SJ11, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.
    View PubMed
  • Leuk Res. 2013 Sep;37(9):1070-6. doi: 10.1016/j.leukres.2013.06.008. Epub 2013 Jun 28. 2013 The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network Tan D11, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, Goh YT, Durie BG, Chng WJ, Lee JH.
    View PubMed
  • Bone Marrow Transplant. 2013 Mar;48(3):425-32. doi: 10.1038/bmt.2012.164. Epub 2012 Sep 3. 2013 Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT Yhim HY11, Kim K, Kim JS, Kang HJ, Kim JA, Min CK, Bae SH, Park E, Yang DH, Suh C, Kim MK, Mun YC, Eom HS, Shin HJ, Yoon HJ, Kwon JH, Lee JH, Kim YS, Yoon SS, Kwak JY.
    View PubMed
  • Am J Hematol. 2013 Jan;88(1):52-5. doi: 10.1002/ajh.23333. Epub 2012 Oct 1. 2013 Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: Results of multicenter analysis Jun HJ11, Kim K, Kim SJ, Mun YC, Bang SM, Won JH, Kim CS, Lee JH; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8. 2013 Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation Lee HS11, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):118-26. doi: 10.1016/j.clml.2011.11.002. Epub 2011 Dec 28. 2012 Lower Dose Dexamethasone/Thalidomide and Zoledronic Acid Every 3 Weeks in Previously Untreated Multiple Myeloma Teoh G11, Chen Y, Kim K, Srivastava A, Pai VR, Yoon SS, Suh C, Kim YK.
    View PubMed
  • Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26. 2012 Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial Kim HJ11, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    View PubMed
  • Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25. 2012 Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity Ahn HK11, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.
    View PubMed
  • Biol Blood Marrow Transplant. 2011 Nov;17(11):1630-7. doi: 10.1016/j.bbmt.2011.04.006. Epub 2011 Apr 23. 2011 Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus Park S11, Kim K, Kim DH, Jang JH, Kim SJ, Kim WS, Jung CW, Koh KC.
    View PubMed
  • Jpn J Clin Oncol. 2011 Mar;41(3):353-7. doi: 10.1093/jjco/hyq194. Epub 2010 Oct 14. 2011 Low-dose Acyclovir is Effective for Prevention of Herpes Zoster in Myeloma Patients Treated with Bortezomib: A Report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study Kim SJ11, Kim K, Do YR, Bae SH, Yang DH, Lee JJ.
    View PubMed
  • Ann Oncol. 2011 Feb;22(2):411-6. doi: 10.1093/annonc/mdq393. Epub 2010 Aug 2. 2011 Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients Kim MK11, Suh C, Lee DH, Min CK, Kim SJ, Kim K, Moon JH, Yoon SS, Lee GW, Kang HJ, Kim SH, Choi CW, Eom HS, Kwak JY, Kim HJ, Mun YC, Bang SM, Lee K, Shin HJ, Lee JH; Korean Multiple Myeloma Working Party.
    View PubMed
  • Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. 2010 Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety Lee SS11, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.
    View PubMed
  • Int J Hematol. 2010 Jul;92(1):52-7. doi: 10.1007/s12185-010-0617-6. Epub 2010 Jun 11. 2010 Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party Lee JH11, Lee DS, Lee JJ, Chang YH, Jin JY, Jo DY, Bang SM, Kim HJ, Kim JS, Kim K, Eom HS, Min CK, Yoon SS, Kim SH, Suh C, Cho KS; Korean Multiple Myeloma Working Party.
    View PubMed
  • Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8. 2010 A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation Kim ST11, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.
    View PubMed
  • Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10. 2010 Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) Eom HS11, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.
    View PubMed
  • Br J Haematol. 2010 May;149(4):537-49. doi: 10.1111/j.1365-2141.2010.08127.x. Epub 2010 Mar 12. 2010 Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo Kim K11, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT.
    View PubMed
  • Cancer Genet Cytogenet. 2010 Mar;197(2):117-21. doi: 10.1016/j.cancergencyto.2009.11.008. 2010 Molecular cytogenetic analysis of Korean patients with Waldenstrom macroglobulinemia Bang SM11, Seo JW, Park KU, Kim SJ, Kim K, Kim SH, Cho SR, Kim HC, Song J, Kim JS, Kim KH, Lee JH, Lee JJ, Shin MG, Suh C, Chi HS, Oh DY, Won JH, Kim HJ, Yoon SS, Lee DS; Korean Multiple Myeloma Working Party (KMMWP).
    View PubMed
  • Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10. 2010 BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients Moon JH11, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.
    View PubMed
  • Ann Hematol. 2010 Feb;89(2):201-6. doi: 10.1007/s00277-009-0807-6. Epub 2009 Aug 25. 2010 Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide Koh Y11, Bang SM, Lee JH, Yoon HJ, Do YR, Ryoo HM, Lee N, Kim SJ, Kim K, Yoon SS, Won JH, Mun YC, Lee MH, Rhee KH, Kim HJ, Eom H, Kim MK, Shin HC; Korean Multiple Myeloma Working Party.
    View PubMed
  • J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16. 2010 Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Choi ER11, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.
    View PubMed
  • Transplantation. 2009 Dec 27;88(12):1349-59. doi: 10.1097/TP.0b013e3181bd7b3a. 2009 Bortezomib Can Suppress Activation of Rapamycin-Resistant Memory T Cells Without Affecting Regulatory T-Cell Viability in Non-Human Primates Kim JS11, Lee JI, Shin JY, Kim SY, Shin JS, Lim JH, Cho HS, Yoon IH, Kim KH, Kim SJ, Park CG.
    View PubMed
  • Acta Haematol. 2009;122(4):200-10. doi: 10.1159/000253027. Epub 2009 Oct 29. 2009 Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry Kim SJ11, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, Kim CS, Sohn SK, Eom HS, Kwak JY, Shim H, Yoon HJ, Jin JY, Min CK, Shin H, Won JH, Lee JJ, Kwon JH, Joo YD, Do YR, Kim SH, Oh S, Suh C, Lee J, Yoon SS, Kim MK, Bang SM, Ryoo HM, Kim BS, Kim H, Kim HJ, Kim YS, Park CW, Lee GW, Shin HJ, Park SK, Park JS, Kim HY, Lee DS, Lee JH; Korean Multiple Myeloma Working Party.
    View PubMed
  • Blood. 2009 Apr 30;113(18):4309-18. doi: 10.1182/blood-2008-10-183772. Epub 2009 Feb 4. 2009 CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells Tai YT11, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC.
    View PubMed
  • Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512. 2009 Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation Kim JS11, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.
    View PubMed
  • J Korean Med Sci. 2008 Apr;23(2):278-83. doi: 10.3346/jkms.2008.23.2.278. 2008 Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia Han AR11, Kim K, Jang JH, Kim WS, Ahn JS, Jung CW, Lee MH, Kang WK.
    View PubMed
  • Cancer Lett. 2007 Dec 8;258(1):90-7. 2007 Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study Oh SY11, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ.
    View PubMed
  • Eur J Haematol. 2007 Oct;79(4):287-91. Epub 2007 Aug 10. 2007 Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease Oh SY11, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ.
    View PubMed
  • Biol Blood Marrow Transplant. 2007 Apr;13(4):463-8. 2007 Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation Uhm JE11, Kim K, Lim TK, Park BB, Park S, Hong YS, Lee SC, Hwang IG, Koh KC, Lee MH, Ahn JS, Kim WS, Jung CW, Kang WK.
    View PubMed
  • Leuk Lymphoma. 2006 Oct;47(10):2128-31. 2006 High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population Cho JH11, Park YH, Kim WS, Oh SY, Cho SI, Kang HJ, Na II, Ryoo BY, Yang SH, Kim K, Jung CW, Park K, Ko YH, Lee SS.
    View PubMed
  • Biol Blood Marrow Transplant. 2006 Aug;12(8):837-44. 2006 New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy Kim H11, Sohn HJ, Kim S, Kim K, Lee JH, Bang SM, Kim DH, Sohn SK, Lee JJ, Suh C.
    View PubMed
  • Int J Hematol. 2006 May;83(4):309-13. 2006 A Multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma Bang SM11, Lee JH, Yoon SS, Park S, Min CK, Kim CC, Suh C, Sohn SK, Min YH, Lee JJ, Kim K, Seong CM, Yoon HJ, Cho KS, Jo DY, Lee KH, Lee NR, Kim CS; Korean Multiple Myeloma Working Party.
    View PubMed
  • Ann Hematol. 2006 May;85(5):285-90. Epub 2006 Mar 4. 2006 Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia Park YH11, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. 2006 Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • Br J Haematol. 2005 Oct;131(1):59-66. 2005 Effects of nuclear factor-kappa B inhibitors and its implication on natural killer T-cell lymphoma cells Kim K11, Ryu K, Ko Y, Park C.
    View PubMed
  • J Cell Biochem. 2005 Mar 1;94(4):695-707. 2005 Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS11, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.
    View PubMed
  • Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8. 2005 Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission Lee SH11, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    View PubMed
  • Cell Signal. 2005 Jan;17(1):111-9. 2005 Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells Park S11, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.
    View PubMed
  • Int J Biochem Cell Biol. 2004 Nov;36(11):2180-95. 2004 L-Ascorbic acid induces apoptosis in acute myeloid leukemia cells via hydrogen peroxide-mediated mechanisms Park S11, Han SS, Park CH, Hahm ER, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Kimler BF, Kim K, Lee JH.
    View PubMed
  • J Cell Biochem. 2004 Oct 1;93(2):257-70. 2004 L-ascorbic acid represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS11, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, Kim WS, Jung CW, Lee MH, Park K, Yang JH, Yoon SS, Riordan NH, Riordan HD, Kimler BF, Park CH, Lee JH, Park S.
    View PubMed
  • 2004 Primary pulmonary non-Hodgkin's lymphoma
    View PubMed
  • Transfusion. 2004 Apr;44(4):533-8. 2004 Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses Suh C11, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, Kim EK, Kim SB, Lee JS, Kim MW, Kim K, Yoon SS.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. 2003 Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed
  • Am J Hematol. 2002 Oct;71(2):75-9. 2002 Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies Kim K11, Lee MH, Kim J, Lee KS, Kim SM, Jung MP, Han J, Sung KW, Kim WS, Jung CW, Yoon SS, Im YH, Kang WK, Park K, Park CH.
    View PubMed
  • Am J Clin Oncol. 2002 Aug;25(4):354-7. 2002 Oxaliplatin and UFT combination chemotherapy in patients with metastatic colorectal cancer Kim K11, Nam E, Lee NS, Lee HR, Lee JY, Lee HR, Park SH, Oh SY, Kim JH, Song SY, Park JO, Kim WS, Jung CW, Im YH, Lee MH, Lee WY, Chun H, Park CH, Park K, Kang WK.
    View PubMed
  • Eur J Cancer. 2002 Jan;38(1):75-81. 2002 Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification Kim K11, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K.
    View PubMed